Quavonlimab

齐沃利单抗

Report date: 2025/10/31 09:25:24

Base Information

Drug NameQuavonlimab
Drug Alias NameMK-1308AK-107
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[23] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhongshan Akeso Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMsd Ireland (Carlow)Merck Sharp & Dohme CorpMerck Sharp & Dohme LLC +[4] 
Inactive CompaniesZhongshan Akeso Biopharma Co Ltd
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A